The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182.
 
Matt D. Galsky
Stock and Other Ownership Interests - Rappta Therapeutics
Consulting or Advisory Role - Aileron Therapeutics; Astellas Pharma; AstraZeneca; BioMotiv; Bristol-Myers Squibb; Dendreon; Dracen; EMD Serono; Genentech; GlaxoSmithKline; Incyte; Inovio Pharmaceuticals; Janssen; Lilly; Merck; Novartis; NuMab; Pfizer; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Sumanta K. Pal
Honoraria - Astellas Pharma; Medivation; Novartis
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Ipsen; Myriad Pharmaceuticals; Novartis; Pfizer
Research Funding - Medivation
 
Amir Mortazavi
Honoraria - Motive Medical Intelligence
Research Funding - Acerta Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Roche (Inst); Seagen (Inst)
 
Matthew I. Milowsky
Consulting or Advisory Role - BioClin Therapeutics
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Incyte (Inst); Inovio Pharmaceuticals (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); X4 Pharma (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
Other Relationship - Asieris Pharmaceuticals
 
Saby George
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; EMD Serono; Exelixis; Genentech/Roche; Janssen Oncology; Novartis; Pfizer; Sanofi
Research Funding - Acceleron Pharma (Inst); Agensys (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst)
 
Sumati Gupta
Stock and Other Ownership Interests - Salarius Pharmaceuticals (I)
Consulting or Advisory Role - Keryx (I)
Research Funding - Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Five Prime Therapeutics (Inst); Hoosier Cancer Research Network (Inst); Incyte (Inst); LSK BioPharma (Inst); LSK BioPharma (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst); Viralytics (Inst)
Travel, Accommodations, Expenses - Keryx (I)
 
Mark T. Fleming
Employment - Virginia Oncology Associates
Consulting or Advisory Role - Janssen Oncology
Speakers' Bureau - Genentech; Janssen Oncology
Travel, Accommodations, Expenses - Genentech; Medivation/Astellas
 
Long H. Dang
No Relationships to Disclose
 
Daniel M. Geynisman
Consulting or Advisory Role - AstraZeneca; Exelixis; Pfizer; Seattle Genetics/Astellas
Research Funding - Astellas Pharma (Inst); Calithera Biosciences (Inst); Genentech (Inst); Merck (Inst)
 
Radhika Walling
No Relationships to Disclose
 
Robert S. Alter
Consulting or Advisory Role - Pfizer/EMD Serono
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Genentech; Janssen Oncology; Merck; Pfizer
 
Erwin L. Robin
No Relationships to Disclose
 
Jue Wang
No Relationships to Disclose
 
Shilpa Gupta
Stock and Other Ownership Interests - Nektar
Honoraria - Janssen Oncology
Consulting or Advisory Role - Exelixis; Genentech; Janssen Oncology; Merck; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Janssen Oncology
Research Funding - Astellas Medivation (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst)
 
David D. Chism
Stock and Other Ownership Interests - Biogen (I)
Travel, Accommodations, Expenses - Lilly
 
Joel Picus
Consulting or Advisory Role - Novo Nordisk; Sanofi
Research Funding - Agensys (Inst); BioClin Therapeutics (Inst); BioClin Therapeutics (Inst); Endocyte (Inst); Innocrin Pharma (Inst); Mirati Therapeutics (Inst); Oncogenex (Inst); Rexahn Pharmaceuticals (Inst); Seagen (Inst); TRACON Pharma (Inst)
 
George Philips
Consulting or Advisory Role - Bayer
 
David I. Quinn
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Dendreon; Exelixis; Genentech/Roche; Janssen Oncology; Merck Sharp & Dohme; Mundipharma; Novartis; Pfizer; Pharmacyclics; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Dendreon; Eisai; EMD Serono; Exelixis; Genentech/Roche; Janssen Oncology; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi; US Biotest
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Millennium (Inst); Sanofi (Inst)
 
Noah M. Hahn
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; Health Advances; Inovio Pharmaceuticals; Merck; Oncogenex; Pieris Pharmaceuticals
Research Funding - Acerta Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Heat Biologics (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Oncogenex (Inst); Principa Biopharma (Inst)
 
Menggang Yu
No Relationships to Disclose